Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Change in Cash (2021 - 2026)

Nuvectis Pharma has reported Change in Cash over the past 6 years, most recently at -$6.5 million for Q1 2026.

  • Quarterly results put Change in Cash at -$6.5 million for Q1 2026, down 157.4% from a year ago — trailing twelve months through Mar 2026 was -$4.7 million (down 145.52% YoY), and the annual figure for FY2025 was $13.1 million, up 2309.27%.
  • Change in Cash reached -$6.5 million in Q1 2026 per NVCT's latest filing, down from -$3.8 million in the prior quarter.
  • Across five years, Change in Cash topped out at $11.3 million in Q1 2025 and bottomed at -$6.5 million in Q1 2026.
  • Median Change in Cash over the past 5 years was -$1.3 million (2024), compared with a mean of $1.1 million.
  • Peak annual rise in Change in Cash hit 3252.37% in 2025, while the deepest fall reached 379.18% in 2025.
  • Over 5 years, Change in Cash stood at -$3.6 million in 2022, then grew by 19.58% to -$2.9 million in 2023, then skyrocketed by 146.51% to $1.4 million in 2024, then crashed by 379.18% to -$3.8 million in 2025, then crashed by 70.8% to -$6.5 million in 2026.
  • Business Quant data shows Change in Cash for NVCT at -$6.5 million in Q1 2026, -$3.8 million in Q4 2025, and $8.6 million in Q3 2025.